Menarini Group and Stemline Collaborate with VisualDx to Enhance Early Detection of BPDCN Using AI/ML Technology

Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...

March 24, 2025 | Monday | News
Paratek Pharmaceuticals to Acquire Optinose for Up to $330 Million, Expanding Portfolio with XHANCE®

Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...

March 21, 2025 | Friday | News
Porton Advanced Partners with Eureka Therapeutics to Accelerate T-Cell Therapy Development

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...

March 21, 2025 | Friday | News
TaiMed Biologics' TMB-365/TMB-380 Shows Strong Phase 2a Results for HIV Maintenance Therapy

TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...

March 19, 2025 | Wednesday | News
Dyne’s DYNE-251 Shows Sustained Functional Gains in DELIVER Trial for DMD

Dyne Therapeutics, Inc., a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscul...

March 18, 2025 | Tuesday | News
AbbVie’s ELAHERE® Shows Major Survival Gains in Final Phase 3 MIRASOL Data

AbbVie  announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab s...

March 18, 2025 | Tuesday | News
Zynext Ventures Invests in Illexcor Therapeutics to Advance Next-Generation Oral Treatment for Sickle Cell Disease

 Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...

March 13, 2025 | Thursday | News
GC Cell Launches Phase 1 Clinical Trial for GCC2005, a Novel CD5 CAR-NK Therapy Targeting T-Cell Lymphomas

GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...

March 13, 2025 | Thursday | News
Gilead Presents Promising Phase 1 Data for Once-Yearly Lenacapavir as HIV Pre-Exposure Prophylaxis

Gilead Sciences, Inc. presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company...

March 12, 2025 | Wednesday | News
Merck ( MSD ) Opens $1 Billion Vaccine Manufacturing Facility in Durham, North Carolina

Merck, known as MSD outside of the United States and Canada, announced  the opening of a new, $1 billion, 225,000-square-foot facility dedicated to va...

March 12, 2025 | Wednesday | News
Doer Bio Completes Phase 2 Enrollment for DR10624 Tri-Agonist in Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

March 10, 2025 | Monday | News
Roche Opens Genentech Innovation Center in Boston, Expands Harvard R&D and AI Collaboration

Roche  announced  the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...

March 10, 2025 | Monday | News
Johnson & Johnson Reports Promising Phase 3 Data for Icotrokinra in Plaque Psoriasis, Launches Head-to-Head Study

Johnson & Johnson announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-t...

March 10, 2025 | Monday | News
ImmunoGenesis Doses First Patient in Phase 1/2 Trial of IMGS-101 Combination Therapy for Advanced Cancers

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced the first patient has been dosed in the co...

March 07, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close